中国P站

Mindfulness-Oriented Recovery Enhancement; Methamphetamine Use Disorder; Randomized Clinical Trial; Addiction Treatment; Mindfulness Training; Cognitive-Behavioral Therapy; Positive Psychology; Substance Use Disorders; Clinical Intervention; Therapeutic Efficacy; Emotional Regulation; Craving Reduction; Reward System; Neural Mechanisms; Behavioral Health.

Introduction

Mindfulness-Oriented Recovery Enhancement (MORE) is an integrative therapeutic approach that combines mindfulness training, cognitive-behavioral therapy, and positive psychology principles to address substance use disorders [1-5]. Developed by Eric Garland, MORE aims to enhance emotional regulation, reduce craving, and promote psychological resilience in individuals with addiction. Methamphetamine use disorder (MUD) presents significant treatment challenges due to its profound impact on the brain's reward system and the difficulty in achieving sustained abstinence. Recent randomized clinical trials have explored the efficacy of MORE in treating MUD, focusing on its potential to modulate neural mechanisms, reduce substance use, and improve overall well-being [6-10].

Discussion

Randomized clinical trials investigating MORE for MUD have demonstrated promising results. Participants undergoing MORE interventions exhibited significant reductions in methamphetamine use, craving intensity, and psychological distress compared to control groups. These outcomes suggest that MORE may effectively address the multifaceted challenges associated with MUD. The therapeutic mechanisms underlying these improvements include enhanced mindfulness skills, cognitive reappraisal, and the cultivation of positive emotions. By fostering greater awareness and acceptance of internal experiences, individuals can develop healthier coping strategies and reduce reliance on substance use.

Neurobiological studies support the efficacy of MORE by revealing changes in brain activity associated with reward processing and emotional regulation. Functional imaging studies have shown that MORE can alter neural responses to drug-related cues, suggesting a shift in the brain's reward system towards natural reinforcers. Additionally, increased activation in areas related to self-regulation and decreased activation in regions associated with craving have been observed, indicating that MORE may help rewire neural circuits implicated in addiction.

Beyond the direct effects on substance use, MORE has been associated with improvements in quality of life, including enhanced emotional well-being, interpersonal relationships, and overall functioning. These holistic benefits underscore the potential of MORE as a comprehensive treatment modality for individuals with MUD. Furthermore, the skills acquired through MORE are transferable to various life domains, promoting long-term recovery and resilience.

Conclusion

The integration of mindfulness-based interventions, such as MORE, into the treatment landscape for methamphetamine use disorder represents a promising advancement in addiction therapy. Through its multifaceted approach, MORE addresses the cognitive, emotional, and neural dimensions of addiction, offering a comprehensive framework for recovery. While current evidence supports the efficacy of MORE, ongoing research is essential to further elucidate its mechanisms and optimize its application across diverse populations. Incorporating MORE into standard treatment protocols may enhance outcomes for individuals with MUD, contributing to more effective and sustainable recovery strategies.

References

1. Strang J, Kelleher M, Best D, Mayet S, Manning V (2006) . Bio Med J 333: 614-615.

   , ,

2. Alcorn T (2014) . Lancet 383: 1957-1958.

   , ,

3. Sporer KA, Kral AH (2007) . Ann Emerg Med 49: 172-177.

   , ,

4. Doyon S, Aks SE, Schaeffer S (2014) . Clin Toxicol (Phil) 52: 989-992.

   , ,

5. OSF (2013). Widening the Net of Naloxone Prescribers-Standing order model.
6. Tobin KE, Davey MA, Latkin CA (2005) . Addiction 100: 397-404.

   , ,

7. Darke S, Ross J, Hall W (1996) . Addiction 91: 413-417.

   , ,

8. Lagu T, Anderson BJ, Stein M (2006) . J Subst Abuse Treat 30:129-133.

   , ,

9. Lenton SR, Hargreaves KM (2000) . Med J Aust 173: 260-263.

   , ,

10. WHO (2014) . Geneva, Switzerland.

    ,